The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The primary goal of the collaboration is joint research into trending and next-generation molecules
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
While Merck can appeal, Halozyme said it expects the order to hold
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Subscribe To Our Newsletter & Stay Updated
